Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,460 | 10 | 74.8% |
| Consulting Fee | $2,062 | 2 | 14.8% |
| Travel and Lodging | $686.85 | 6 | 4.9% |
| Food and Beverage | $670.35 | 13 | 4.8% |
| Education | $99.00 | 1 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $13,216 | 25 | $0 (2021) |
| Celgene Corporation | $561.75 | 1 | $0 (2021) |
| Janssen Biotech, Inc. | $182.27 | 5 | $0 (2022) |
| Adaptive Biotechnologies Corporation | $17.68 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $41.73 | 2 | Janssen Biotech, Inc. ($41.73) |
| 2021 | $13,936 | 30 | Incyte Corporation ($13,216) |
All Payment Transactions
32 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/26/2022 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $23.22 | General |
| Category: Oncology | ||||||
| 06/14/2022 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $18.51 | General |
| Category: Oncology | ||||||
| 12/23/2021 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 12/14/2021 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $24.55 | General |
| Category: Hematology/Oncology | ||||||
| 12/08/2021 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | ||||||
| 11/22/2021 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $570.00 | General |
| Category: Hematology/Oncology | ||||||
| 11/18/2021 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Education | In-kind items and services | $99.00 | General |
| Category: Oncology | ||||||
| 11/11/2021 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $27.02 | General |
| Category: Oncology | ||||||
| 11/04/2021 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $24.62 | General |
| Category: Hematology/Oncology | ||||||
| 10/20/2021 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,140.00 | General |
| Category: Hematology/Oncology | ||||||
| 10/07/2021 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $114.84 | General |
| Category: Hematology/Oncology | ||||||
| 10/01/2021 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $20.16 | General |
| Category: Hematology/Oncology | ||||||
| 08/11/2021 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,140.00 | General |
| Category: Hematology/Oncology | ||||||
| 08/05/2021 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Hematology/Oncology | ||||||
| 08/01/2021 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $22.40 | General |
| Category: Hematology/Oncology | ||||||
| 07/30/2021 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,520.00 | General |
| Category: Hematology/Oncology | ||||||
| 07/30/2021 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $580.00 | General |
| Category: Hematology/Oncology | ||||||
| 07/01/2021 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $380.00 | General |
| Category: Hematology/Oncology | ||||||
| 06/16/2021 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,520.00 | General |
| Category: Hematology/Oncology | ||||||
| 06/15/2021 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $15.15 | General |
| Category: Hematology/Oncology | ||||||
| 06/08/2021 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $198.77 | General |
| Category: Hematology/Oncology | ||||||
| 06/08/2021 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $97.72 | General |
| Category: Hematology/Oncology | ||||||
| 06/01/2021 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $188.16 | General |
| Category: Hematology/Oncology | ||||||
| 05/28/2021 | Celgene Corporation | REBLOZYL (Biological) | Consulting Fee | Cash or cash equivalent | $561.75 | General |
| Category: Hematology | ||||||
| 05/20/2021 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,520.00 | General |
| Category: Hematology/Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 7 | 222 | 285 | $62,955 | $11,480 |
| 2020 | 4 | 122 | 134 | $45,674 | $5,549 |
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 60 | 80 | $12,600 | $3,697 | 29.3% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 71 | 97 | $10,927 | $2,453 | 22.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 25 | 31 | $7,538 | $2,103 | 27.9% |
| 38222 | Diagnostic aspirations and biopsies of bone marrow | Facility | 2021 | 27 | 27 | $19,015 | $1,470 | 7.7% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2021 | 16 | 27 | $3,037 | $632.25 | 20.8% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 12 | 12 | $1,902 | $583.22 | 30.7% |
| 38220 | Aspiration of bone marrow | Facility | 2021 | 11 | 11 | $7,936 | $540.43 | 6.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 57 | 67 | $10,224 | $2,154 | 21.1% |
| 38222 | Bone marrow biopsy and aspiration | Facility | 2020 | 30 | 30 | $20,418 | $1,510 | 7.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 22 | 23 | $5,458 | $1,275 | 23.4% |
| 38220 | Diagnostic bone marrow aspiration | Facility | 2020 | 13 | 14 | $9,574 | $609.51 | 6.4% |
About Madeleine Henriquez, PA-C
Madeleine Henriquez, PA-C is a Physician Assistant healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/13/2015. The National Provider Identifier (NPI) number assigned to this provider is 1487025797.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Madeleine Henriquez, PA-C has received a total of $13,978 in payments from pharmaceutical and medical device companies, with $41.73 received in 2022. These payments were reported across 32 transactions from 4 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($10,460).
As a Medicare-enrolled provider, Henriquez has provided services to 344 Medicare beneficiaries, totaling 419 services with total Medicare billing of $17,030. Data is available for 2 years (2020–2021), covering 11 distinct procedure/service records.
Practice Information
- Specialty Physician Assistant
- Location Houston, TX
- Active Since 10/13/2015
- Last Updated 09/10/2019
- Taxonomy Code 363A00000X
- Entity Type Individual
- NPI Number 1487025797
Products in Payments
- JAKAFI (Drug) $11,716
- REBLOZYL (Biological) $561.75
- IMBRUVICA (Drug) $167.75
- clonoSEQ (Device) $17.68
- DARZALEX (Biological) $14.52
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Physician Assistant Doctors in Houston
Amanda Wilhite, Pa-C, PA-C
Physician Assistant — Payments: $136,303
Christina Yazdani, Pa-C, PA-C
Physician Assistant — Payments: $48,235
Jacqueline Weatherly, Pa-C, PA-C
Physician Assistant — Payments: $46,977
Julie Huynh-Lu, Pa-C, PA-C
Physician Assistant — Payments: $45,677
Virginia Schneider, Pa, PA
Physician Assistant — Payments: $43,222
Mr. James Smith, Pa-C, PA-C
Physician Assistant — Payments: $42,324